VistaGen Therapeutics Reports Third Quarter Fiscal 2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
230
VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results

SOUTH SAN FRANCISCO, CA --(Marketwired - February 12, 2018) - VistaGen Therapeutics, Inc. ( NASDAQ : VTGN ), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported financial results for its third fiscal quarter ended December 31, 2017.

"Building on our significant progress last quarter, our team is prepared and eager to launch, during the current quarter, our AV-101 Phase 2 clinical development program, initially focused on adjunctive treatment of Major Depressive Disorder patients with an inadequate response to standard, FDA-approved antidepressants. This year has the potential to be transformative for VistaGen and the millions of depression patients seeking new generation treatment options that are fundamentally different from all currently available therapies," commented Shawn Singh, Chief Executive Officer of VistaGen.

Financial Results for the Fiscal Quarter Ended December 31, 2017: Net loss attributable to common stockholders for the fiscal quarter ended December 31, 2017 was approximately $3.5 million, compared to $2.9 million for the fiscal quarter ended December 31, 2016.

Research and development expense totaled approximately $1.6 million for the fiscal quarter ended December 31, 2017, compared with approximately $1.6 million for the fiscal quarter ended December 31, 2016. Research and development expense was primarily attributable to the Company's development of AV-101, its oral, new generation CNS drug candidate initially focused on displacing adjunctive atypical antipsychotics in the current Major Depressive Disorder (MDD) treatment paradigm, including final preparations to launch its AV-101 MDD Phase 2 adjunctive treatment study in patients with an inadequate response to standard FDA-approved antidepressants.

General and administrative expense was approximately $1.3 million in the fiscal quarter ended December 31, 2017, compared to approximately $2.3 million in the fiscal quarter ended December 31, 2016. The decrease was primarily attributable to decreased professional services expenses, a decrease in noncash expense attributable to grants of common stock for services, and a decrease in noncash warrant modification expense, partially offset by increased salary and benefits and noncash stock compensation expenses.

At December 31, 2017, the Company had cash and cash equivalents of approximately $13.0 million, compared to approximately $2.9 million at March 31, 2017.

About VistaGen VistaGen Therapeutics, Inc. ( NASDAQ : VTGN ), is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for MDD. AV-101's mechanism of action is fundamentally different from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the U.S. National Institute of Mental Health (NIMH) in a small Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with an inadequate response to standard, FDA-approved antidepressants. Dr. Maurizio Fava of Harvard University is the Principal Investigator of the VistaGen's AV-101 MDD Phase 2 adjunctive treatment study. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington's disease, Parkinson's disease levodopa-induced dyskinesia (PD LID) and other CNS diseases and disorders where modulation of the NMDA receptors, activation of AMPA pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit.

For more information, please visit www.vistagen.com and connect with VistaGen on: Twitter LinkedIn Facebook

Forward-Looking Statements The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the successful launch, continuation and results of the NIMH's Phase 2 (MDD monotherapy) and/or the Company's planned Phase 2 (MDD adjunctive treatment) clinical studies of AV-101, allowance of patent applications and continued protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the AV-101 Phase 2 clinical development activities described above. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov . VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

   
VISTAGEN THERAPEUTICS  
Condensed Consolidated Balance Sheets  
Amounts in Dollars  
             
             
    December 31,     March 31,  
    2017     2017  
    (Unaudited)        
             
ASSETS  
Current assets:                
  Cash and cash equivalents   $ 13,031,800     $ 2,921,300  
  Prepaid expenses and other current assets     940,400       456,600  
      Total current assets     13,972,200       3,377,900  
Property and equipment, net     222,800       286,500  
Security deposits and other assets     47,800       47,800  
      Total assets   $ 14,242,800     $ 3,712,200  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current liabilities:                
  Accounts payable   $ 509,300     $ 867,300  
  Accrued expenses     770,900       443,000  
  Current notes payable     43,700       54,800  
  Capital lease obligations     2,600       2,400  
      Total current liabilities     1,326,500       1,367,500  
                   
Non-current liabilities:                
  Accrued dividends on Series B Preferred Stock     2,344,400       1,577,800  
  Deferred rent liability     299,100       139,200  
  Capital lease obligations     10,000       11,900  
    Total non-current liabilities     2,653,500       1,728,900  
    Total liabilities     3,980,000       3,096,400  
                 
Commitments and contingencies                
                 
Stockholders' equity:                
  Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2017 and March 31, 2017:                
    Series A Preferred, 500,000 shares authorized, issued and outstanding at December 31, 2017 and March 31, 2017     500       500  
    Series B Preferred; 4,000,000 shares authorized at December 31, 2017 and March 31, 2017; 1,160,240 shares issued and outstanding at December 31, 2017 and March 31, 2017     1,200       1,200  
    Series C Preferred; 3,000,000 shares authorized at December 31, 2017 and March 31, 2017; 2,318,012 shares issued and outstanding at December 31, 2017 and March 31, 2017     2,300       2,300  
  Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized at December 31, 2017 and March 31, 2017, respectively; 22,723,504 and 8,974,386 shares issued and outstanding at December 31, 2017 and March 31, 2017, respectively     22,700       9,000  
  Additional paid-in capital     166,669,200       146,569,600  
  Treasury stock, at cost, 135,665 shares of common stock held at December 31, 2017 and March 31, 2017     (3,968,100 )     (3,968,100 )
  Accumulated deficit     (152,465,000 )     (141,998,700 )
      Total stockholders' equity     10,262,800       615,800  
      Total liabilities and stockholders' equity   $ 14,242,800     $ 3,712,200  
                 
   
VISTAGEN THERAPEUTICS  
STATEMENT OF OPERATIONS  
Amounts in Dollars, except share amounts  
                 
UNAUDITED  
                 
  Three Months Ended December 31,   Nine Months Ended December 31,  
  2017   2016   2017   2016  
Revenues:                        
  Sublicense revenue $ -   $ 1,250,000   $ -   $ 1,250,000  
    Total revenues   -     1,250,000     -     1,250,000  
Operating expenses:                        
  Research and development   1,601,800     1,611,000     5,124,600     4,042,800  
  General and administrative   1,266,000     2,276,600     4,997,400     4,907,800  
    Total operating expenses   2,867,800     3,887,600     10,122,000     8,950,600  
Loss from operations   (2,867,800 )   (2,637,600 )   (10,122,000 )   (7,700,600 )
Other expenses, net:                        
  Interest expense, net   (2,000 )   (900 )   (7,700 )   (3,700 )
  Loss on extinguishment of accounts payable   (135,000 )   -     (135,000 )   -  
                         
Loss before income taxes   (3,004,800 )   (2,638,500 )   (10,264,700 )   (7,704,300 )
Income taxes   -     -     (2,400 )   (2,400 )
Net loss and comprehensive loss   (3,004,800 )   (2,638,500 )   (10,267,100 )   (7,706,700 )
                         
  Accrued dividend on Series B Preferred stock   (263,000 )   (237,700 )   (766,600 )   (1,018,500 )
  Deemed dividend from trigger of down round provision feature   (199,200 )   -     (199,200 )   -  
  Deemed dividend on Series B Preferred Units   -     -     -     (111,100 )
                         
Net loss attributable to common stockholders $ (3,467,000 ) $ (2,876,200 ) $ (11,232,900 ) $ (8,836,300 )
                         
Basic and diluted net loss attributable to common stockholders per common share $ (0.25 ) $ (0.34 ) $ (1.03 ) $ (1.23 )
                         
Weighted average shares used in computing basic and diluted net loss attributable to common stockholders per common share   13,895,642     8,381,824     10,947,556     7,181,307  
                         

Company Contact Mark A. McPartland VistaGen Therapeutics Inc. Phone: +1 (650) 577-3600 Email: IR@vistagen.com Investor Contact: Valter Pinto / Allison Soss KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212) 896-1267 Email: VistaGen@KCSA.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 120

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 100

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 31

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 71

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading